Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-15 (canceled)

16. (Currently Amended) A pharmaceutical formulation for peroral single daily application, comprising clarithromycin or a derivative thereof and a mixture of a fatty and hydrophilic component, wherein the fatty component comprises about 10-36 weight percentof the formulation, and wherein the hydrophilic component comprises about 5-18 weight percent of the formulation

17. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, further comprising a surfactant.

18. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, further comprising a pH modulator.

19. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, wherein the fatty component comprises glyceryl behenate.

20. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, wherein the hydrophilic component comprises hydroxypropyl methylcellulose of low viscosity.

21. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 19, wherein the hydroxypropyl methylcellulose has a viscosity of about 15 cP.

22. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 17, wherein the surfactant comprises sodium docusate.

23. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 18, wherein the pH modulator comprises a phosphate buffer.

24. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, characterized in that it is in the form of a tablet.

25. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim ~~23~~ 24, characterized in that the tablet is lacquered.

26. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim ~~23~~ 24, characterized in that on the tablet an acid-resistant coating is applied.

27. (Currently Amended) A process for the preparation of a pharmaceutical formulation for peroral single daily application comprising clarithromycin or a derivative thereof and a mixture of a fatty and a hydrophilic component, wherein the fatty component comprises about 10-36 weight percent of the formulation, and wherein the hydrophilic component comprises about 5-18 weight percent of the formulation, which comprises forming a homogeneous mixture thereof and direct compressing said mixture into tablet form without use of solvents.

28. (Currently Amended) ~~A~~ The process according to claim 27 comprising sieving the homogeneous mixture prior to compressing the mixture into tablet form.

29. (New) The pharmaceutical formulation according to claim 24, wherein the fatty component is a sustained released component that provides sustained release of the clarithromycin or clarithromycin derivative, and wherein the hydrophilic component forms a viscous layer in an aqueous medium through which the clarithromycin or clarithromycin

derivative diffuses upon solubilization, and wherein the fatty component and the hydrophilic component are in a weight ration to each other between about 2:1 to 10:1, thereby effective to provide controlled release of the clarithromycin or clarithromycin derivative over about a twenty-four hour period.

30. (New) The pharmaceutical formulation according to claim 29, wherein the fatty component is selected from a group of fatty components consisting of triglycerides of higher saturated fatty acids, hydrogenated oils and mixtures thereof.

31. (New) The pharmaceutical formulation according to claim 29, wherein the fatty component is glyceryl behenate.

32. (New) The pharmaceutical formulation according to claim 29, wherein the hydrophilic component is selected from a group of hydrophilic components consisting of alkyl-substituted cellulose ethers, fatty alcohols, polysaccharides, large specific surface absorbents and mixtures thereof.

33. (New) The pharmaceutical formulation according to claim 32, wherein the hydrophilic component is selected from a group of hydrophilic components consisting of alkyl-substituted cellulose ethers and mixtures thereof.

34. (New) The pharmaceutical formulation according to claim 33, wherein the fatty component is glyceryl behenate, and wherein the hydrophilic component is hydroxypropyl methylcellulose.